Corient Private Wealth
VIR icon

Corient Private Wealth’s Vir Biotechnology VIR Stock Holding History

Corient Private Wealth’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Buy
311,002
+17,314
+6% +$165K ﹤0.01% 1089
2026
Q1 		$2.63M Buy
293,688
+32,986
+13% +$263K ﹤0.01% 1118
2025
Q4 		$1.57M Buy
260,702
+1,006
+0.4% +$5.99K ﹤0.01% 1270
2025
Q3 		$1.48M Buy
259,696
+354
+0.1% +$1.81K ﹤0.01% 1220
2025
Q2 		$1.31M Buy
259,342
+966
+0.4% +$5.18K ﹤0.01% 1235
2025
Q1 		$1.67M Buy
258,376
+856
+0.3% +$7.61K ﹤0.01% 1042
2024
Q4 		$1.89M Sell
257,520
-25,545
-9% -$201K ﹤0.01% 1029
2024
Q3 		$2.12M Buy
283,065
+16,968
+6% +$147K ﹤0.01% 1067
2024
Q2 		$2.37M Sell
266,097
-3,815
-1% -$36.6K ﹤0.01% 958
2024
Q1 		$2.73M Buy
269,912
+2,633
+1% +$26.8K ﹤0.01% 888
2023
Q4 		$2.69M Buy
267,279
+27,115
+11% +$248K ﹤0.01% 881
2023
Q3 		$2.25M Sell
240,164
-838
-0.3% -$12K 0.01% 866
2023
Q2 		$5.91M Buy
241,002
+167
+0.1% +$4.19K 0.01% 584
2023
Q1 		$5.6M Buy
+240,835
New +$6.16M 0.02% 558

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Corient Private Wealth's VIR Position: Q2 2026 in Review

Corient Private Wealth increased its Vir Biotechnology (VIR) stake by 5.9% in Q2 2026, buying an estimated $165K and bringing the position to 311,002 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1089.

Corient Private Wealth first reported a position in VIR in Q1 2023 and has held it in 14 quarters since. The position peaked at $5.91M in Q2 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Corient Private Wealth held 311,002 shares of Vir Biotechnology worth $3.17M as of Q2 2026.
  • Corient Private Wealth bought 17,314 Vir Biotechnology shares in Q2 2026, an estimated $165K.
  • Vir Biotechnology made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1089 holding.
  • Corient Private Wealth first reported a position in Vir Biotechnology in Q1 2023 and has held it in 14 quarters since.
  • Corient Private Wealth's Vir Biotechnology position peaked at $5.91M in Q2 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.